June 12 (Reuters) - Novo Nordisk said on

Thursday it plans to start late-stage trials of its experimental

weight-loss drug amycretin in injection and oral forms during

the first quarter of 2026 for adults who are overweight or

obese.

The decision to advance the trials is based on feedback

received from regulatory authorities in interactions following

the end of its mid-stage trials, the company said.

Amycretin, the Danish drugmaker's next generation obesity

drug, has a dual mode action. Like its popular weight-loss drug

Wegovy, amycretin mimics the gut hormone GLP-1, but it also

mimics the effect of a hunger-suppressing pancreatic hormone

called amylin.